Genera Research Ltd. participated in the second edition of BioPharma & LabXperience 2026, held on June 2 in Zagreb. The conference brought together professionals from the pharmaceutical and biopharmaceutical industries, laboratory sciences, healthcare, regulatory affairs, quality management, academia, and technology-driven sectors to discuss current trends and innovations shaping the future of life sciences. As part of the conference programme, Dora Adanić, COO of Genera Research, contributed as both a speaker and panelist. She introduced the development pathway of the OSTEOproDENT® project, highlighting the translation of scientific research into innovative regenerative medicine solutions for bone regeneration. The presentation provided insights into the challenges and opportunities associated with transforming research results into clinically relevant technologies. In addition, Dora Adanić participated in an expert panel discussion focused on the role of artificial intelligence, compliance, and digital solutions in modern laboratory and quality management environments. The discussion brought together experts from different sectors to exchange perspectives on technological advancements and future directions in laboratory and healthcare settings. The event provided an excellent platform for knowledge exchange, networking, and discussions on innovation, digitalization, and collaboration across the life sciences ecosystem. Genera Research would like to thank Sartorius Croatia-Libra Elektronik d.o.o. for the invitation and the successful organization of this valuable industry event. We look forward to continuing the dialogue and fostering new collaborations that support innovation in regenerative medicine and biotechnology.

Genera Research Ltd. participated in the symposium “Knowledge and Technology Transfer in Regenerative Medicine”, held on May 8, 2026 at the Croatian Academy of Sciences and Arts (HAZU) in Zagreb. The symposium brought together leading Croatian experts in translational and regenerative medicine to discuss the journey from scientific discovery to clinical application and commercialization, with a strong focus on innovation, intellectual property, and collaboration between academia and industry. During the symposium, presentations covered the development of Osteogrow technology, preclinical research of Osteogrow-C, advanced regenerative medicine formulations, and ongoing projects focused on bone regeneration and dental applications, including OSTEOforUNION and OSTEOproDENT®. The discussions highlighted the importance of connecting academic research, translational science, and industry collaboration in order to bring innovative regenerative medicine solutions closer to clinical practice and patients. Slobodan Vukičević, CEO of Genera Research Ltd. presented the development of Osteogrow - an innovative drug for bone regeneration. Dora Adanić, COO of Genera Research Ltd. , presented the hashtag OSTEOforUNION and OSTEOproDENT® projects. We are proud to contribute to initiatives that strengthen the path from scientific discovery to real-world medical impact.